Sugi Predict

Sugi Predict / Compounds / SCHEMBL178408

SCHEMBL178408

SCHEMBL178408

CCCCCNC(=O)OC(C)(C)C

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.70
▸ EPHX1 P07099 7/20 0.62
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ MAOA P21397 1/20 0.60
▸ MAOB P27338 1/20 0.60
▸ CA12 O43570 2/20 0.57
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ ACHE P22303 3/20 0.52
▸ LMNA P02545 1/20 0.51
▸ TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30024827 0.98 TDP1 (0.68) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL3365771 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL4553865 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL8737682 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL14877952 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL25319217 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL16436993 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
Ammonia Solution, Strong SCHEMBL6805262 0.98 TDP1 (0.68) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL7106115 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA
SCHEMBL28923405 0.98 TDP1 (0.73) TDP1EPHX1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111471021-B Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith 西格诺药品有限公司 2024-04-02 — — CN disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 — — WO disclosed
CN-117715642-A Heterocyclic compounds and methods of use 薛定谔公司 2024-03-15 — — CN disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 — — EP disclosed
CN-110914240-B Norbornenone compounds releasing carbon monoxide 奥塔哥创新有限公司 2024-02-20 — — CN disclosed
CN-115894303-B Preparation method of (3-amino bicyclo [1.1.1] pentane-1-yl) carbamic acid tert-butyl ester and intermediate thereof 安徽皓元药业有限公司 2024-01-26 — — CN disclosed
US-11859019-B2 Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha OHIO STATE INNOVATION FOUNDATION (US) 2024-01-02 — — US disclosed
US-11858912-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-01-02 — — US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 — — CN disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
US-20030087935-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T (US) 2003-05-08 — — US disclosed
US-20030069275-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T (US) 2003-04-10 — — US disclosed
CN-1101816-C Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 2003-02-19 — — CN disclosed
CN-1374955-A Oxazole and thiazole derivatives as antidiabetic and antiobesity agents BRISTOL MYERS SQUIBB CO (US) 2002-10-16 — — CN disclosed
EP-1218361-A1 OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-07-03 — — EP disclosed
US-6414002-B1 ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS BRISTOL-MYERS SQUIBB COMPANY 2002-07-02 — — US disclosed
WO-2001021602-A1 OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-03-29 — — WO disclosed
CN-1054598-C Pharmacologically active hydrazine derivatives and processes for preparation thereof NORVATIS CO (CH) 2000-07-19 — — CN disclosed
CN-1193623-A Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 1998-09-23 — — CN disclosed
CN-1068333-A Has hydrazine analog derivative of pharmacologically active and preparation method thereof CIBA GEIGY AG (CH) 1993-01-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858912-B2 Heterocyclic compounds F12, C1R, MRPL21 TDP1 3036/4885EPHX1 2042/4885MEN1 244/4885
US-20030069275-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, PNLIP TDP1 4331/4885EPHX1 2658/4885MEN1 2985/4885
US-11859019-B2 Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha NFKBIA, TNFRSF1A, NFATC1 TDP1 1725/4885EPHX1 1688/4885MEN1 4436/4885
US-20030087935-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, PNLIP TDP1 4331/4885EPHX1 2658/4885MEN1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.